Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Radical hysterectomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Radical hysterectomy. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-005518-11 Sponsor Protocol Number: 2006-10 Start Date*: 2007-01-24
    Sponsor Name:Örebro University Hospital
    Full Title: Epidural analgesia or opatient controlled regional analgesia for radical Retropubic Prostatectomy. A randomized, double-blind study.
    Medical condition: Postoperative pain after radical retropubic prostatectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005407-40 Sponsor Protocol Number: 2011-425 Start Date*: 2013-02-07
    Sponsor Name:Thomas Bergholt
    Full Title: Peroperative Tranexamic acid as prophylaxis of bleeding related to benign hysterectomy - a randomized, placebo-controlled trial
    Medical condition: Bleeding related to benign hysterectomy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10066252 Total vaginal hysterectomy LLT
    14.1 100000004865 10046913 Vaginal hysterectomy LLT
    14.1 100000004865 10021152 Hysterectomy (ovaries conserved) LLT
    14.1 100000004865 10057318 Total hysterectomy LLT
    14.1 100000004865 10059806 Ovariohysterectomy LLT
    14.1 100000004865 10000075 Abdominal hysterectomy LLT
    14.1 100000004865 10027801 Modified vaginal hysterectomy LLT
    14.1 100000004865 10023692 Laparoscopically assisted hysterectomy LLT
    14.1 100000004865 10044080 Total abdominal hysterectomy LLT
    14.1 100000004865 10042429 Subtotal hysterectomy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004055-35 Sponsor Protocol Number: Bay a 0128/12002 Start Date*: 2006-01-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, randomized, double blind, placebo controlled study to investigate the efficacy and safety of Aprotinin on transfusion requirements in patients with bladder cancer undergoing radical...
    Medical condition: Radical or total cystectomy on patients with bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057191 Transfusion related complications HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002251-33 Sponsor Protocol Number: 01 Start Date*: 2006-10-10
    Sponsor Name:University of Vienna
    Full Title: Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer .
    Medical condition: Twenty-five patients with cervical carcinoma (T2Nx or TxN1) will be included in the present study. In addition to the routine pre-therapeutical staging of cervical cancer, 18FAZA PET will be perfor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002244-23 Sponsor Protocol Number: INCB24360-901 Start Date*: 2021-07-28
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Randomized, Phase 2, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse ...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001216-19 Sponsor Protocol Number: Start Date*: 2014-11-13
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose e...
    Medical condition: glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004562-35 Sponsor Protocol Number: Ketolorac_001 Start Date*: 2021-11-25
    Sponsor Name:Jessa ziekenhuis vzw
    Full Title: Low dose versus normal dose ketorolac for postoperative pain after prostatectomy and hysterectomy: a Double-blind Randomized Controlled Non-inferiority Trial
    Medical condition: Prostatectomy Hysterectomy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10061916 Prostatectomy PT
    20.0 10042613 - Surgical and medical procedures 10021151 Hysterectomy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004867-19 Sponsor Protocol Number: v1330032015 Start Date*: 2015-02-24
    Sponsor Name:Clinic for General Anesthesiology, Intensive Care and Pain Management
    Full Title: Perioperative fluid management in patients receiving major abdominal surgery – Effects of normal saline versus an acetate buffered balanced infusion solution on the necessity of catecholamines for ...
    Medical condition: hemodynamic stability of patients undergoing major surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002620-36 Sponsor Protocol Number: 17000139BLC3001 Start Date*: 2021-05-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma...
    Medical condition: Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned) PL (Completed) BE (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023081-52 Sponsor Protocol Number: ENGOT-EN2-DGCG Start Date*: 2011-01-25
    Sponsor Name:Danish Gynaecological Cancer Group (DGCG)
    Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
    Medical condition: Endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014738 Endometrial cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014739 Endometrial cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011542-25 Sponsor Protocol Number: C-2009-01 Start Date*: 2010-01-07
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: CIRCCa(Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent c...
    Medical condition: Metastatic/ Recurrent carinoma of cervix
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008224 Cervical adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006214-26 Sponsor Protocol Number: GU07-123 Start Date*: 2009-09-07
    Sponsor Name:Hoosier Oncology Group
    Full Title: Phase II Trial of Neoadjuvent Cisplatin, Gemcitabine and Sunitinib Malate followed by radical cystectomy for transitional Cell Carcinoma (TCC) of the bladder
    Medical condition: operable bladder cancer (T2 to T4a) lymph node negative disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004585-18 Sponsor Protocol Number: KKS-190 Start Date*: 2013-08-27
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. Randomized, controlled study to compare the analgesic therapy with t...
    Medical condition: Hysterectomy with ASA 1-3, Prostatectomy with ASA 1-3, Nephrectomy with ASA 1-3
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021151 Hysterectomy PT
    14.1 10042613 - Surgical and medical procedures 10029116 Nephrectomy PT
    14.1 10042613 - Surgical and medical procedures 10061916 Prostatectomy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005504-28 Sponsor Protocol Number: EORTC-1525-LCG Start Date*: 2017-12-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
    Medical condition: type B3 thymoma and thymic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061031 Thymoma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Temporarily Halted) NL (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002824-98 Sponsor Protocol Number: ANE_HEPUNOX Start Date*: 2016-10-20
    Sponsor Name:Fundació Hospital Vall Hebron Institut de Recerca
    Full Title: Comparison of three techniques in the management of the postoperatory acute pain, after a general anesthesia based on the control of the nociception.
    Medical condition: Acute postoperative pain
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10002323 Anesthesia general LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002678-11 Sponsor Protocol Number: ICO-13-001 Start Date*: 2018-06-07
    Sponsor Name:Institut Català d’Oncologia
    Full Title: An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer
    Medical condition: early breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-000601-27 Sponsor Protocol Number: MERCURY Start Date*: 2022-09-27
    Sponsor Name:Fondazione GONO
    Full Title: Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial
    Medical condition: The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002816-22 Sponsor Protocol Number: CTL-002-002 Start Date*: 2023-03-09
    Sponsor Name:Catalym GmbH
    Full Title: A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
    Medical condition: Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003102-40 Sponsor Protocol Number: M17CPF Start Date*: 2018-11-01
    Sponsor Name:NKI-AVL
    Full Title: Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
    Medical condition: women ≥18 and ≤ 40 years with FIGO stage Ib1 cervical carcinoma with tumor measuring ≥ 2 cm and ≤ 4 cm on physical examination and imaging
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008230 Cervix neoplasms malignant HLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000994-69 Sponsor Protocol Number: SOV302 Start Date*: 2004-11-11
    Sponsor Name:Amersham Buchler GmbH & Co KG an affiliate of GE Healthcare Bio-Sciences
    Full Title: A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries
    Medical condition: Suspected or proven chronic PAOD predominantly located in the aorto-iliac region of Fontaine Stages IIb to IV (ie, Rutherford Stages I3-III), or presents with an ankle brachial pressure index of <0...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10062585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 11:20:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA